# Diabetic Gastroparesis Study 05

> **NCT03786380** · PHASE3 · TERMINATED · sponsor: **Allergan** · enrollment: 202 (actual)

## Conditions studied

- Gastroparesis

## Interventions

- **DRUG:** Relamorelin 10 μg

## Key facts

- **NCT ID:** NCT03786380
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-20
- **Primary completion:** 2020-10-05
- **Final completion:** 2020-10-05
- **Target enrollment:** 202 (ACTUAL)
- **Why stopped:** The Relamorelin program is being terminated solely based on a business decision.
- **Last updated:** 2021-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786380, "Diabetic Gastroparesis Study 05". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03786380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*